Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy

NCT07573696 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Nonsmall Cell Lung Cancer Stage III

Interventions

DRUG: After neoadjuvant alpelisib combined with chemotherapy, a multidisciplinary decision was made

Sponsor

Wen-zhao ZHONG